scispace - formally typeset
P

Ping Li

Researcher at GlaxoSmithKline

Publications -  34
Citations -  894

Ping Li is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: AS03 & Vaccination. The author has an hindex of 16, co-authored 34 publications receiving 818 citations.

Papers
More filters
Journal ArticleDOI

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial

TL;DR: The authors compared inactivated seasonal quadrivalent influenza vaccines (QIV) versus TIV (15 and 7.5 μg hemagglutinin [HA] for each influenza strain, respectively) in a phase II randomized (1 : 1), observer-blind trial in US children 6-35 months of age (identifier NCT01974895).
Journal ArticleDOI

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials

TL;DR: The results do not support an association between AS03-adjuvanted H5N1 and A(H1N1)pdm09 vaccines and the AEs collected in the trials included in the analysis.
Journal ArticleDOI

Rapid Immunization Against H5N1: A Randomized Trial Evaluating Homologous and Cross-Reactive Immune Responses to AS03A-Adjuvanted Vaccination in Adults

TL;DR: The AS03A-adjuvanted H5N1 vaccine in accelerated schedules offers a robust immune response against vaccine homologous and drift variant strains, allowing consideration of compressed vaccination intervals.